RFK Jr's CDC Panel Recommends Merck's RSV Shot For Infants

The U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Merck & Co Inc’s (NYSE:MRK) Enflonsia (clesrovimab-cfor) as an option for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months of age who are born during or entering their first RSV season.

With a five-to-two majority, RFK Jr.’s newly constituted committee made its first ruling. This body was formed after RFK Jr. entirely replaced the previous 17-member panel with his own selections.

The ACIP also voted to include Enflonsia in the Vaccines for Children Program, an essential step in ensuring broad access to this preventive option for ...